Seretide Evohaler Inhaler 25/125 is a synthetic corticosteroid with mainly glucocorticocoid activity. Seretide Evohaler Inhaler 25/125 is used by oral inhalation for the prophylactic treatment of asthma. Seretide Evohaler Inhaler 25/125 is reported to have a local effect on lungs without causing significant systemic effects, reduces airway inflammation and hence reduces oedema and secretions of mucous into the airway. It also is used as a nasal spray in the treatment of allergic rhinitis. When applied topically used in the treatment of various skin disorders. Fluticasone approved by FDA in december 1990
Seretide Evohaler Inhaler 25/125 is primarily indicated in conditions like Allergic rhinitis, Asthma, Atopic eczema, Contact sensitivity reactions, Dermatitis, Discoid eczema, Discoid lupus erythematosus, Eczema, Infantile eczema, Neurodermatoses, Parennial rhinitis, Perennial rhinitis, Psoriasis, Purigo nodularis, Seborrheic dermatitis, and can also be given in adjunctive therapy as an alternative drug of choice in Generalised erythroderma, Insect bite reactions, Liver transplant.
Seretide Evohaler Inhaler 25/125 is contraindicated in conditions like Acne vulgaris, Rosacea,Perioral dermatitis, Hypersensitivity,Primary cutaneous viral infection,Perianal and genital pruritis.
The severe or irreversible adverse effects of Seretide Evohaler Inhaler 25/125, which give rise to further complications include Glaucoma, Cataract, Growth retardation, Adrenocortical suppression, Decrease in bone mineral density. The symptomatic adverse reactions produced by Seretide Evohaler Inhaler 25/125 are more or less tolerable and if they become severe, they can be treated symptomatically, these include Pruritus, Dysphonia, Allergic contact dermatitis, Cough, Oral candidiasis, Local burning, Hyperpigmentation, Hypertrichosis, Vocal cord myopathy, Throat irritation, Superficial blood vessels dilatation, Superficial blood vessels thinning, Secondary dermatitis, Hypercortisolism
It should be used with caution in patients with active tuberculosis infection of respiratory tract or in untreated fungal, bacterial or systemic viral infections. Corticosteroids should only be used systemically with great caution in the presence of congestive heart failure (CHF), recent myocardial infraction (MI), hypertension, diabetes mellitus, epilepsy, glaucoma, hypothyroidism, liver failure, osteoporosis, peptic ulceration or renal impairment. Children may be at increase risk of some adverse effects, corticosteroid causes growth retardation and prolonged use is rarely justified. Live vaccine should not be given to patients receiving high dose systemic corticosteroid therapy nor for atleast 3 months afterwards, killed vaccine or toxoids may be given,